William Aird/X
Jul 7, 2025, 11:42
What Drives Essential Thrombocythemia? Dr. William Aird on the Pathophysiology of Platelet Overproduction
Dr. William Aird, Professor of Medicine at Harvard Medical School, has posted on X:
“Essential Thrombocythemia (ET) Pathophysiology
ET is driven by one of 3 mutations:
- JAK2 V617F → cytokine-independent signaling
- CALR → abnormal MPL activation
- MPL → constitutive TPO receptor signaling
All lead to unchecked megakaryocyte proliferation and ↑ platelets.”
Curious about what drives Essential Thrombocythemia? Here’s a quick look at the mutations involved.
Explore more on Hemostasis Today.
-
Mar 3, 2026, 17:12Matteo Foschi: Cancer Worsens Prognosis after Breakthrough Ischemic Stroke Despite Oral Anticoagulation
-
Mar 3, 2026, 17:04Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
-
Mar 3, 2026, 16:58Non-Carrier Mothers of Inv22 Hemophilia A Patients Frequently Harbor Additional F8 Gene Rearrangements – JTH
-
Mar 3, 2026, 16:53Valentina Rossi: Addressing Inflammation and Immune Mechanisms in Cardiomyopathy Management
-
Mar 3, 2026, 16:45Emmanuel J Favaloro: New Publication on Artificial Intelligence in Thrombosis and Hemostasis in CCLM
-
Mar 3, 2026, 16:32Scott E. Smith: Why Hematology Research Is the True Leader of all Medical Disciplines
-
Mar 3, 2026, 16:21Tareq Abadl: Why HIV Antibodies Stay Positive Even When Viral Load Is Zero?
-
Mar 3, 2026, 16:12Mark Crowther Congratulates Mary Cushman on Her Appointment as ISTH President
-
Mar 3, 2026, 15:42Cheng-Hock Toh։ The Unrecognised Central Role of Hematology in Healthcare Design